Canada approves second generic version of Ozempic
Tweet
Share
E-mail
FILE PHOTO: Pens for the diabetes drug Ozempic sit on a production line to be packaged at the Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo
OTTAWA, May 1 (Reuters) - The Canadian health regulator said on Friday that it had approved Canada-based Apotex's generic version of semaglutide, making it the second copycat version of Danish drugmaker Novo Nordisk's blockbuster diabetes drug Ozempic authorized in the country.
(Reporting by Ismail Shakil and Ryan Patrick Jones; Editing by Caitlin Webber)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BOJ to speed up its tightening campaign, raise key rate to 1.25% in September: Reuters poll
- Syria's Kurdish-led SDF dissolves as part of integration with Damascus
- US appeals court blocks FCC plan to expand discounted political advertising rates
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
